This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Findings Leading to Discontinuation of the 2.5-mg/day Estrogen Group

The Coronary Drug Project Research Group

JAMA. 1973;226(6):652-657.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

As noted in two previous reports from the Coronary Drug Project,^1,2 physicians face a difficult dilemma concerning pharmacologic therapy of hyperlipidemia-hyperlipoproteinemia in an attempt to prevent first or recurrent episodes of clinical coronary heart disease. It is known that susceptibility to premature coronary heart disease is directly related to serum levels of cholesterol, and of low-density and very-low-density lipoproteins. It is also known that elevated serum levels of lipids-lipoproteins frequently can be influenced over long periods of time by available drugs. However, answers to key questions about these pharmaceutical agents are lacking. Do they prevent coronary heart disease and prolong life? Are they reasonably safe in long-term usage?

The Coronary Drug Project—a nationwide collaborative study sponsored by the National Heart and Lung Institute—is the most extensive effort ever undertaken to answer these questions with regard to men who have already experienced one or more episodes of myocardial infarction.^1-5 . . . [Full Text PDF of this Article]

Footnotes
For a complete list of the key bodies of the Coronary Drug Project and senior staff members see p 657.

Reprint requests to 303 E Chicago Ave, Chicago 60611 (Dr. Stamler).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?